Weidentified borrrelidin, a member of macrolide antibiotic, as an inhibitor of a cyclindependent kinase of the budding yeast, Cdc28/Cln2. A 50% inhibition concentration (IC50) of borrelidin for Cdc28/Cln2 was 24^m. In addition, borrelidin arrests both haploid and diploid cells in Gl phase at the point indistinguishable from that of a-mating pheromone, at
concentrations not affecting the gross protein synthesis. Although the inhibition of CDK activity may not be a solo cause of the Gl arrest, our results indicate that borrelidin is a potential lead compound for developing novel CDKinhibitors of higher eukaryotes.
The cell cycle progression of eukaryotes is tightly regulated by cyclin-dependent kinase (CDK) family. CDKs are inactive in monomeric form and activated by binding to cyclines, a diverse family of proteins whose levels oscillate during the cell cycle. Regulation of CDKactivity occurs at multiple levels, including cyclin synthesis and degradation, activating and inactivating phosphorylation, CDKinhibitor proteins (CKIs) and subcellular localization1~3). In mammaliancells, the progression of cells from Gl to S phase is regulated by retinoblastoma gene product (Rb protein), a tumor suppressor gene, that blocks the expression of a set of genes required for enter the S phase4)5). CDKs inactivate Rb by phosphorylation and promote cell cycle progression. Because alteration of Rb and/or alteration or absence of CKIshave been associated with many cancers, chemical modulators of CDKactivity is an attractive target for cancer chemotherapy. Indeed, two direct CDK inhibitors, flavopiridol (polyhydroxylated flavone) and UCN-01(purine derivative) were developed and reported to show promising results in early clinical trials6).
Borrelidin was isolated as an antibiotic in 19497). This pp.84 -90 drug shows weak antibacterial activity against commonly used test strains but shows antiviral and anti-tumor activity8'9). More recently, borrelidin was found to block angiogenesis in rat aorta matrix culture10). The major cause of antibiotic activity of borrelidin was reported to be the inhibition of threonyl tRNA synthasen) and Wakabayashi et al. observed that the drug inhibits both threonyl tRNA synthase and protein synthesis of cultured rat cells10). However, the IC50 value for anti-angiogenesis activity of borrelidin was 0.4ng/ml, while that of protein synthesis was over 20ng/ml, suggesting some uncharacterized activity of the drug.
Weidentified borrelidin as a cell cycle modulator of budding yeast, Saccharomyces cerevisiae. In this report, we describe our finding that borrelidin is a novel inhibitor of the budding yeast CDK.
Materials and Methods
Strains and Media S. cerevisiae strains used were W303(ura3-l Ieu2-3J12 Filters were dried and counted by a liquid scintillation c ounter.
Order-of-function Mapping
A reciprocal shift experiment was performed as described15).
Samples were taken at 15-minutes intervals, fixed with 3% formaldehyde and scored for cell number and emergence of buds. 85 Immunoprecipitation and Kinase Assay YET49cells grown to mid-log phase in YPDwere induced for production of HA-tagged Cln2p by shifting to YPGalactose (YPD containing 2% galactose in stead of glucose) for 3 hours. For preparation of cell lysate, cells were harvested by centrifugation at 4°C and washed twice with ice cold lysis buffer (50mMTris-HCl, pH 7.5, 2mM sodium pyrophosphate, 1% sodium deoxycholate, 1%
Triton X-100, 0.1% sodium dodecylsulfate, 2mMPMSF, 5 /ig/ml pepstatin, 5 /xg/ml leupeptin, 20 /ig/ml aprotinin), resuspended in the same buffer and broken with glass beads by two bursts of vigorous vortexing for 5 minutes at 4°C. 
Results and Discussion

Borrelidin Blocks Gl Progression
In order to identify novel cell cycle inhibitors, we screened for activity that arrests yeast cell growth in unbudded Gl stage, on culture supernatant of several thousand strains of actinomycestes. Among those, broth of a strain No. SNA24891 showed potent activity. The active compound was purified from a culture broth of this strain by ethyl acetate extraction, silica gel column chromatography and HPLC. UV and NMR spectra indicated that it was identical to borrelidin ( Fig. 1, data not shown). The purified drug was dissolved in ethanol at The half-inhibitory concentration of borrelidin on the yeast cell growth estimated by fold increase of cell number during 10 hours incubation was 2^g/ml (4jllm) and over 90%inhibition was observed at 4^ag/ml. The effect of the drug was fully reversible, i.e., the ratio of colony formation of the cells treated with lO jUg/ml ofborrelidin for 10 hours was indistiguishable from that of mock treated cells (data not shown).
To assess the effect of borrelidin on cell cycle progression, we examined the DNAcontent of the cells by fluorescence-activated cell sorting (FACS) analysis. As shown in Fig. 2 , the accumulation of the cells with 1C DNA content was observed in the presence of 4^/g/ml of borrelidin after 4-hours incubation, compared to the culture added with drug vehicle, ethanol. Morphology of the cells and nuclei stained with propidium iodide showed that over 85% of the cells treated with 4jiglmX of borrelidin for 6 hours have no bud and single nucleus. These observations indicate that the drug arrests the cells in Gl phase of the cell cycle. This effect of borrelidin was observed with both MATa-and M4ra-mating type haploid cells and also with MATala diploid cells (data not shown). Fig. 3 , the 20minutes treatment with borrelidin did not block [35S]methionine incorporation up to lO^g/ml, while the treatment with cycloheximide as a control blocked the incorporation nearly completely at the concentration of 1 /ig/ml. We also carried out this experiment with longer drug-treatment period (40 minutes) and obtained the same result (data not shown). These results suggest that the Gl block phenotype of borrelidin does not depend on the inhibition of protein synthesis. 87 The Borrelidin Block Point is in Late Gl at START To determine the borrelidin block point within Gl, we performed an order-of-function (reciprocal shift) analysis using the mating pheromone a-factor15). This maps the borrelidin block point relative to the a-factor arrest point, START.Following release from a-factor block, the cells added with drug vehicle emerged new bud and synchronously divided by 120 minutes. On the other hand, the cells added with 4/ig/ml borrelidin did not form new bud during 240-minutes incubation (Fig. 4, A and C) . This result indicated that the block point of borrelidin is after or similar to that of a-factor. Interestingly, in the borrelidinto-a-factor shift experiment, the cells released from borrelidin were fully sensitive to a-factor and formed shmoo (Fig. 4, B and D, data of shmoo formation not shown). Therefore, the block point of borrelidin was concluded to be similar to that of a-factor. W303-1A cells treated with 10^g/ml of a-factor (A and C) or 4/zg/ml ofborrelidin (B and D) were washed and released to drug free medium (containing 0.08% ethanol, open circle) and medium containing 4^g/ml borrelidin (A and C) or lO^ug/ml of a-factor (B and D) (closed circle), respectively. At indicated times, aliquots were withdrawn, fixed with 3%formaldehyde and scored for cell numberand bud emergenceunder a microscope. The experiment was carried out twice with good consistency. (Fig. 5, B) We also tested the effect of borrelidin on Cdc28/Clb2 kinase, a major CDK functioning in the G2/M phase of the cell cycle, by using immunoprecipitates from the cells expressing HA-tagged Clb2. The addition of 25/ig/ml borrelidin into the reaction decreased the phosphorylation of HI by 15% (data not shown). The inhibitory activity of borrelidin on Cdc28/Clb2 kinase seemed to be weaker than that on Cdc28/Cln2 kinase. Further analyses will be required to understand the effect of borrelidin on yeast CDKsas well as on the mechanisms of the drug action on cell growth.
There are several small molecular CDK inhibitors that have so far been characterized: the purine-based compounds (olomoucine and its analogues), butyrolactone, flavopiridols (flavopiridol and deschloroflavopiridol), staurosporines (staurosporine and UCN-01), polysulfates (suramin), 9-hydroxydllipticine and paullones6). Each is either a natural product or derivative of one with a distinct chemical structure. However, no memberof macrolides was reported as CDK inhibitor to date. CDKs are conserved through evolution and many CDKinhibitors inhibit both human and yeast CDKs21). Our results suggest that borrelidin is a potential lead compoundto develop potent anti-tumor agents.
